RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT04514653 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

BIOLOGICAL: Ranibizumab
GENETIC: ABBV-RGX-314 Dose 1
GENETIC: ABBV-RGX-314 Dose 2
GENETIC: ABBV-RGX-314 Dose 3
DRUG: Local Steroid
DRUG: Topical Steroid
GENETIC: ABBV-RGX-314 Dose 4

Sponsor

AbbVie

Collaborators

[object Object]